Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease

Study Met its Primary Endpoint
GENEVA, October 25, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today that the two-year Phase III REFLEX 1 study met its primary
endpoint by demonstrating that Rebif(R) (interferon beta-1a) significantly
delayed conversion to multiple sclerosis (MS) diagnosed according to the
McDonald criteria 2 in patients with a first clinical … Read more »».

Non-communicable Diseases Mortality to Cost a Whopping USD237 Billion to the National Income by 2015

Experts Say Universal Access to Preventive and Curative Intervention is Crucial

NEW DELHI, October 25, 2010 – Health experts participating at a roundtable organised by India Health
Progress(IHP) on economic and social impact of non-communicable diseases in
India are of the opinion that a concerted effort is required to address the
growing burden.
A review …. Original article  : Non-communicable Diseases Mortality to Cost a Whopping USD237 Billion to the National Income by 2015.

MarketsandMarkets New Report – Global Ophthalmology Drugs & Devices Market

DALLAS, October 25, 2010 – Read The Complete TOC Here:
www.marketsandmarkets.com/Market-Reports/ophthalmology-drugs-devices-2
18.html

Global ophthalmology drug and devices market is witnessing a significant
growth due to the increasing incidence and prevalence of eye related
disorders such as presbyopia, macular degeneration, and diabetic retinopathy
among the aging population. With the introduction of ophthalmic devices
equipped with sophisticated technologies, people … Original source on Gaea Times at : MarketsandMarkets New Report – Global Ophthalmology Drugs & Devices Market.

Elsevier Introduces Protein Viewer, Bringing Science to Life

New Feature on SciVerse ScienceDirect Presents Proteins in Three Dimensions, Allowing Manipulation of Molecular Structures, to the Benefit of the Reader

AMSTERDAM, October 25, 2010 – Elsevier, a world-leading publisher of scientific, medical and technical
products and services, introduces Protein Viewer, a new, interactive feature
on SciVerse ScienceDirect for the Journal of Molecular Biology (JMB)
(www.sciencedirect.com/science/journal/00222836). With Protein … Original article on : Elsevier Introduces Protein Viewer, Bringing Science to Life.

Positive Results From LigoCyte’s Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting

Intranasal Norovirus VLP Vaccine Demonstrates Clinical Efficacy When Compared to Placebo in Phase I/II Trial

BOZEMAN, Montana, October 25, 2010 – LigoCyte Pharmaceuticals, Inc., a private, clinical-stage
biopharmaceuticals company developing innovative vaccine products, today
announced positive results from a Phase I/II challenge study of its norovirus
virus-like particle (VLP) vaccine candidate. Baylor College of Medicine's
Robert Atmar, M.D., the …. Read the original article  : Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting.

Infosys Science Foundation Announces Winners of the Infosys Prize 2010

Winners to be Awarded Rs.50 lakh in Recognition of Their Outstanding Contributions to Scientific Research

BANGALORE, India, October 25, 2010 – The Infosys Science Foundation today announced the winners of
the Infosys Prize 2010 recognizing outstanding contributions to scientific
research that have impacted India. The winners across five categories -
Mathematical Sciences, Physical Sciences, Engineering and Computer Science,
Life …. Source  : Infosys Science Foundation Announces Winners of the Infosys Prize 2010.

PharmaVentures Acts as Advisor and Broker to Dr Reddy’s to Identify and Secure Product Marketing Opportunities for the Russian/CIS Market

OXFORD, England, October 26, 2010 – PharmaVentures Ltd announced today that it had acted as the advisor and
broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its
successful marketing and distribution agreement with the UK healthcare
company Vitabiotics Ltd for a range of nutraceutical products. The agreement
provides Dr Reddy's exclusive marketing rights in the Russian/CIS [..] Read the original article: here.

Shire Receives INTUNIV(TM) Paragraph IV Notice Letter

Watson is the Fourth Paragraph IV Filer Against INTUNIV
DUBLIN, October 26, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that it has received a Paragraph IV
Notice Letter from Watson Laboratories, Inc. ("Watson") advising of the
filing of an Abbreviated New Drug Application ("ANDA") for a generic version
of Shire's 4 mg … Read the original article on Gaea Times at : Shire Receives INTUNIV(TM) Paragraph IV Notice Letter.

Bupa Report Reveals That Half of all UK Parents Send Children To School When Ill

LONDON, October 26, 2010 – Bupa has revealed that fever, diarrhoea or vomiting are not enough to
stop British parents sending their offspring to school. New research from the
Bupa 'How Are You Britain?' report reveals half of all parents in the UK
admit to sending their children to school or nursery when they are feeling
poorly and … Read more »».

Sirius Genomics Announces Issuance of U.S. Patent

VANCOUVER, October 26, 2010 – Sirius Genomics, a developer of companion diagnostics, announced today
that U.S. Patent No. 7,820,376 entitled "Protein C Polymorphisms" has been
issued by the United States Patent and Trademark Office. The patent relates
to a novel use of a Single Nucleotide Polymorphism (SNP) located in the
Protein C gene.

"The patent …. Original source  : Sirius Genomics Announces Issuance of U.S. Patent.

Henry Schein Enters Fast-Growing Dental Market in Turkey

Full-Service Distributor Holds a Leading Market Position
MELVILLE, New York, October 27, 2010 – Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of health care
products and services to office-based practitioners, today announced it has
acquired a 50% non-consolidating interest in Guney Dis Deposu (Guney), a
full-service dental distribution business headquartered in Istanbul, Turkey.
The remaining 50% will be …. Source  : Henry Schein Enters Fast-Growing Dental Market in Turkey.

Elsevier Celebrates Nine 2010 Nobel Laureates and Honors Achievements With Freely Available Prize-Winning Research

Tribute Website Provides Laureate Research on In-Vitro Fertilization, Revolutionary Processes in Physics and Chemistry, and Labor and Housing Market Theory

AMSTERDAM, October 27, 2010 – Elsevier, the leading scientific, technical and medical
publisher announced today the launch of a Nobel tribute website
(www.elsevier.com/nobel) to honor nine 2010 Nobel laureates and
provide free access to their research published by …. Read the original article  : here.

Torchmark Corporation Reports Third Quarter 2010 Results

MCKINNEY, Texas, October 27, 2010 – Torchmark Corporation (NYSE: TMK) reported today that for the quarter
ended September 30, 2010, net income was $1.41 per share compared with $1.22
per share for the year-ago quarter. Net operating income for the quarter was
$1.63 per share, a 10% per share increase compared with $1.48 per share for
the year-ago …. Read the original article  : here.

Chronic Migraine Is Associated With Reduced Household Income and Greater Headache Impact

CHICAGO, October 29, 2010 – New data presented today at The 2010 European Headache and Migraine Trust
International Congress (EHMTIC) shows that persons with chronic migraine
(headache on greater than or equal to 15 days per month) are much more likely
to have annual household incomes below US$30,000 than those with episodic
migraine (headache on < 15 days …. Source article  : Chronic Migraine Is Associated With Reduced Household Income and Greater Headache Impact.

Doctor to World Community: Eat Right and Thrive!

Joel Fuhrman, M.D., To Offer Message of Hope and Healing at London Scientific Conference

LONDON, October 28, 2010 – Joel Fuhrman, M.D., a world leader in nutritional science, will share his
discoveries leading to permanent weight loss and the reversal of chronic
health conditions such as heart disease, diabetes and high blood pressure now
threatening the world community …. Original source  : Doctor to World Community: Eat Right and Thrive!.

Taking Control of Diabetes: Support World Diabetes Day (14th November 2010)

LONDON, October 28, 2010 – Diabetic Hypoglycemia supports World Diabetes Day on the 14th November
2010 in raising the global awareness of diabetes (
www.worlddiabetesday.org/).

The theme of World Diabetes Day in 2010 is "Let's take control of
diabetes. Now", which marks the second year of the five-year focus on
diabetes education and prevention, the …. Source  : Taking Control of Diabetes: Support World Diabetes Day (14th November 2010).

Merck Serono Sells Th??ramex to Teva for EUR 265 Million

Acquisition Will Provide Teva With a Strong Platform to Expand its Global Women's Health Business

GENEVA, October 28, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today that it will sell Th??ramex, its Monaco-based pharmaceutical
company specialized in women's health and gynecology, to Teva. Merck KGaA and
Teva have signed an agreement whereby Teva …. Original article on Gaea Times at  : Merck Serono Sells Th??ramex to Teva for EUR 265 Million.

Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist

Potential Therapy for Lung Fibrosis of Scleroderma and Idiopathic Pulmonary Fibrosis

SAN DIEGO, October 28, 2010 – Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase
1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy
subjects.
"We are excited to begin our journey exploring the therapeutic value of
AM152, a …. Original source  : Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist.

Pfizer’s Lyrica(R) (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan

First Treatment Approved for Common Pain Conditions Filling Important Unmet Need for Patients in Japan

NEW YORK, October 28, 2010 – Pfizer Inc.(NYSE: PFE) announced today that the Japanese Ministry of
Health, Labour and Welfare approved Lyrica(R) (pregabalin) capsules for the
treatment of peripheral neuropathic pain. This follows the recent approval in
Japan of Lyrica for the treatment … Read more >>.

Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder

PHILADELPHIA, October 29, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced results from a Phase 2 signal
finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in
patients who have had residual symptoms of depression following treatment
with LEXAPRO(R) (escitlopram) for Major Depressive Disorder (MDD). Based on
these findings, Shire intends to advance …. Source article  : Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder.

Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging

DUBLIN, October 29, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to
September 30, 2010.

Financial Highlights … Read the original article on Gaea Times at : Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging.